Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines
← catalyst calendarNCT07415551 · readout in 304 d
Sponsored by Yuhan Corporation (industry) · 000100.KS — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
150estimated
Sites
30
Countries
Bulgaria, China, Poland +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-26 | actual | When the study began enrolling |
| Primary completion | 2027-06-19 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-07-24 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Allergic Diseases
- Chronic Spontaneous Urticaria (CSU)
Interventions
- Drug: Lesigercept
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange from baseline Urticaria Activity Score over 7 days (UAS7) at Week 12
measured From first dose to Week 12
Permalink · 000100.KS's whole pipeline · Catalyst calendar · Every registered study · What changed